Skip to main content
Top
Published in: Current Rheumatology Reports 1/2010

01-02-2010

The Roll of Toll-like Receptors in the Antiphospholipid Syndrome

Authors: Julia Hurst, Mareike Lorenz, Nadine Prinz, Philipp von Landenberg

Published in: Current Rheumatology Reports | Issue 1/2010

Login to get access

Abstract

The antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis, recurrent fetal loss, and the presence of antiphospholipid antibodies (aPL). Recent data support the idea that the thrombotic activity in APS patients is attributed to enhanced cytokine release via activation of certain Toll-like receptors. To investigate these mechanisms more precisely, different experimental approaches were used to investigate this connection in detail. IgG fractions and/or monoclonal aPL, either generated from murine or human B cells were intensely used for stimulation experiments of monocytes, endothelial cells, or dendritic cells. All these stimuli induced an enhanced expression and secretion of cytokines, especially tumor necrosis factor (TNF)-α, caused by specific regulation or activation of Toll-like receptors. Using specific agonists or inhibitors could confirm the causal connection of these stimulatory effects. This review focuses on these recent developments, connecting the binding of aPL with the activity of Toll-like receptors, especially in monocytes, endothelial cells, and dendritic cells.
Literature
1.
go back to reference Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309–1311.CrossRefPubMed Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309–1311.CrossRefPubMed
2.
go back to reference Asherson RA: The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 1998, 7:S55–S62.CrossRefPubMed Asherson RA: The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 1998, 7:S55–S62.CrossRefPubMed
3.
go back to reference von Landenberg C, Lackner KJ, von Landenberg P, et al.: Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999, 13:215–223.CrossRef von Landenberg C, Lackner KJ, von Landenberg P, et al.: Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999, 13:215–223.CrossRef
4.
go back to reference Lopez-Pedrera C, Buendia P, Aguirre MA, et al.: Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus 2006, 15:161–166.CrossRefPubMed Lopez-Pedrera C, Buendia P, Aguirre MA, et al.: Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus 2006, 15:161–166.CrossRefPubMed
5.
go back to reference Pierangeli SS, Vega-Ostertag M, Harris EN: Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004, 114:467–476.CrossRefPubMed Pierangeli SS, Vega-Ostertag M, Harris EN: Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004, 114:467–476.CrossRefPubMed
6.
go back to reference Wolberg AS, Roubey RA: Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res 2004, 114:391–396.CrossRefPubMed Wolberg AS, Roubey RA: Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res 2004, 114:391–396.CrossRefPubMed
7.
go back to reference Lopez-Pedrera C, Buendia P, Cuadrado MJ, et al.: Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54:301–311.CrossRefPubMed Lopez-Pedrera C, Buendia P, Cuadrado MJ, et al.: Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54:301–311.CrossRefPubMed
8.
go back to reference Vollmer J, Tluk S, Schmitz C, et al.: Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575–1585.CrossRefPubMed Vollmer J, Tluk S, Schmitz C, et al.: Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575–1585.CrossRefPubMed
9.
go back to reference Meroni PL, Raschi E, Testoni C, et al.: Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 2004, 3:510–515.CrossRefPubMed Meroni PL, Raschi E, Testoni C, et al.: Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 2004, 3:510–515.CrossRefPubMed
10.
go back to reference • Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.: Toll like Receptor 4 is involved in antiphospholipid- mediated thrombosis: In vivo studies. Ann Rheum Dis 2007, 66:1327–1333. This article provides the first Evidence that TLRs are involved in the aPS pathophysiology. • Pierangeli SS, Vega-Ostertag ME, Raschi E, et al.: Toll like Receptor 4 is involved in antiphospholipid- mediated thrombosis: In vivo studies. Ann Rheum Dis 2007, 66:1327–1333. This article provides the first Evidence that TLRs are involved in the aPS pathophysiology.
11.
go back to reference Jurk M, Heil F, Vollmer J, et al.: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.CrossRefPubMed Jurk M, Heil F, Vollmer J, et al.: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.CrossRefPubMed
12.
go back to reference Raschi E, Testoni C, Bosisio D, et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 1:3495–3500.CrossRef Raschi E, Testoni C, Bosisio D, et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 1:3495–3500.CrossRef
13.
go back to reference Barrat FJ, Meeker T, Gregorio J, et al.: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131–1139.CrossRefPubMed Barrat FJ, Meeker T, Gregorio J, et al.: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131–1139.CrossRefPubMed
14.
go back to reference Christensen SR, Shupe J, Nickerson K, et al.: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417–428.CrossRefPubMed Christensen SR, Shupe J, Nickerson K, et al.: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417–428.CrossRefPubMed
15.
go back to reference Ehlers M, Fukuyama H, McGaha TL, et al.: TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006, 203:553–561.CrossRefPubMed Ehlers M, Fukuyama H, McGaha TL, et al.: TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006, 203:553–561.CrossRefPubMed
16.
go back to reference Leadbetter EA, Rifkin IR, Hohlbaum AM, et al.: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603–607.CrossRefPubMed Leadbetter EA, Rifkin IR, Hohlbaum AM, et al.: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603–607.CrossRefPubMed
17.
go back to reference Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006, 124:783–801.CrossRefPubMed Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006, 124:783–801.CrossRefPubMed
18.
go back to reference Andreakos E, Foxwell B, Feldmann M: Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004, 202:250–265.CrossRefPubMed Andreakos E, Foxwell B, Feldmann M: Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004, 202:250–265.CrossRefPubMed
19.
go back to reference Rifkin IR, Leadbetter EA, Busconi L, et al.: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27–42.CrossRefPubMed Rifkin IR, Leadbetter EA, Busconi L, et al.: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27–42.CrossRefPubMed
21.
go back to reference • Sorice M, Longo A, Capozzi A, et al.: Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56:2687–2697. This article provides the first direct connection of TLR activity with the aPL binding. • Sorice M, Longo A, Capozzi A, et al.: Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56:2687–2697. This article provides the first direct connection of TLR activity with the aPL binding.
22.
go back to reference Hakomori S, Handa K, Iwabuchi K, et al.: New insights in glycosphingolipid function: signaling domain, a cell surface assembly of glycosphingolipids with signal transducer molecules, involved in cell adhesion coupled with signaling. Glycobiology 1998, 8:xi–xix. Hakomori S, Handa K, Iwabuchi K, et al.: New insights in glycosphingolipid function: signaling domain, a cell surface assembly of glycosphingolipids with signal transducer molecules, involved in cell adhesion coupled with signaling. Glycobiology 1998, 8:xi–xix.
23.
go back to reference Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169–174.CrossRefPubMed Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169–174.CrossRefPubMed
24.
go back to reference Buttari B, Profumo E, Mattei V, et al.: Oxidized 2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005, 106:3880–3887.CrossRefPubMed Buttari B, Profumo E, Mattei V, et al.: Oxidized 2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005, 106:3880–3887.CrossRefPubMed
25.
go back to reference Lutters BC, Derksen RH, Tekelenburg WL, et al.: Dimers of 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2. J Biol Chem 2003, 278:33831–33838.CrossRefPubMed Lutters BC, Derksen RH, Tekelenburg WL, et al.: Dimers of 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2. J Biol Chem 2003, 278:33831–33838.CrossRefPubMed
26.
go back to reference Ma K, Simantov R, Zhang JC, et al.: High affinity binding of 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541–15548.CrossRefPubMed Ma K, Simantov R, Zhang JC, et al.: High affinity binding of 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541–15548.CrossRefPubMed
27.
go back to reference Muzio M, Natoli G, Saccani S, et al.: The human Toll signaling pathway: divergence of NF-kB and JNK/SAPK activation upstream of TRAF6. J Exp Med 1998, 187:2097–3101.CrossRefPubMed Muzio M, Natoli G, Saccani S, et al.: The human Toll signaling pathway: divergence of NF-kB and JNK/SAPK activation upstream of TRAF6. J Exp Med 1998, 187:2097–3101.CrossRefPubMed
28.
go back to reference Medzhitov R, Preston-Hurlburt P, Kopp E, et al.: MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1999, 2:253–258.CrossRef Medzhitov R, Preston-Hurlburt P, Kopp E, et al.: MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1999, 2:253–258.CrossRef
29.
go back to reference Cockrell E, Espinola RG, McCrae KR: Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 2008, 17:943–951.CrossRefPubMed Cockrell E, Espinola RG, McCrae KR: Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 2008, 17:943–951.CrossRefPubMed
30.
go back to reference Cervera R, Piette JC, Font J, et al.: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019–1027.CrossRefPubMed Cervera R, Piette JC, Font J, et al.: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019–1027.CrossRefPubMed
31.
go back to reference Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al.: Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009, 114:3074–3083.CrossRefPubMed Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al.: Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009, 114:3074–3083.CrossRefPubMed
32.
go back to reference Blank M, Krause I, Fridkin M, et al.: Bacterial induction of autoantibodies to 2-glycoprotein-1 accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002, 109:797–804.PubMed Blank M, Krause I, Fridkin M, et al.: Bacterial induction of autoantibodies to 2-glycoprotein-1 accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002, 109:797–804.PubMed
33.
go back to reference Döring Y, Hurst J, Lorenz M, et al.: Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2009 May 18 (Epub ahead of print). Döring Y, Hurst J, Lorenz M, et al.: Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2009 May 18 (Epub ahead of print).
34.
go back to reference Wang J, Shao Y, Bennett TA, et al.: The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J Biol Chem 2006, 281:37427–37434.CrossRefPubMed Wang J, Shao Y, Bennett TA, et al.: The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J Biol Chem 2006, 281:37427–37434.CrossRefPubMed
35.
go back to reference Hornung V, Rothenfusser S, Britsch S, et al.: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531–4537.PubMed Hornung V, Rothenfusser S, Britsch S, et al.: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531–4537.PubMed
36.
go back to reference Nagase H, Okugawa S, Ota Y, et al.: Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 2003, 171:3977–3982.PubMed Nagase H, Okugawa S, Ota Y, et al.: Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 2003, 171:3977–3982.PubMed
37.
go back to reference Gorden KB, Gorski KS, Gibson SJ, et al.: Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005, 174:1259–1268.PubMed Gorden KB, Gorski KS, Gibson SJ, et al.: Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005, 174:1259–1268.PubMed
38.
go back to reference Cesarman-Maus G, Rios-Luna NP, Deora AB, et al.: Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375–4382.CrossRefPubMed Cesarman-Maus G, Rios-Luna NP, Deora AB, et al.: Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375–4382.CrossRefPubMed
39.
go back to reference Subramanian S, Tus K, Li QZ, et al.: A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 2006, 103:9970–9975.CrossRefPubMed Subramanian S, Tus K, Li QZ, et al.: A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 2006, 103:9970–9975.CrossRefPubMed
40.
go back to reference Berman J, Girardi G, Salmon JE: TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485–490.PubMed Berman J, Girardi G, Salmon JE: TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485–490.PubMed
41.
go back to reference Forastiero RR, Martinuzzo ME, de Larranaga GF: Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005, 14:129–136.CrossRefPubMed Forastiero RR, Martinuzzo ME, de Larranaga GF: Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005, 14:129–136.CrossRefPubMed
42.
go back to reference Bernot D, Peiretti F, Canault M, et al.: Upregulation of TNF-alpha-induced ICAM-1 surface expression by adenylate cyclase-dependent pathway in human endothelial cells. J Cell Physiol 2005, 202:434–441.CrossRefPubMed Bernot D, Peiretti F, Canault M, et al.: Upregulation of TNF-alpha-induced ICAM-1 surface expression by adenylate cyclase-dependent pathway in human endothelial cells. J Cell Physiol 2005, 202:434–441.CrossRefPubMed
43.
go back to reference Giannakopoulos B, Passam F, Rahgozar S, Krilis SA: Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007, 109:422–430.CrossRefPubMed Giannakopoulos B, Passam F, Rahgozar S, Krilis SA: Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007, 109:422–430.CrossRefPubMed
44.
go back to reference Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169–174.CrossRefPubMed Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169–174.CrossRefPubMed
45.
go back to reference Hezi-Yamit A, Wong PW, Bien-Ly N, et al.: Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci U S A 2005, 102:12077–12082.CrossRefPubMed Hezi-Yamit A, Wong PW, Bien-Ly N, et al.: Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci U S A 2005, 102:12077–12082.CrossRefPubMed
46.
go back to reference Bevilacqua MP, Pober JS, Majeau GR, et al.: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986, 83:4533–4537.CrossRefPubMed Bevilacqua MP, Pober JS, Majeau GR, et al.: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986, 83:4533–4537.CrossRefPubMed
47.
go back to reference Cekaite L, Furset G, Hovig E, Sioud M: Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 2007, 365:90–108.CrossRefPubMed Cekaite L, Furset G, Hovig E, Sioud M: Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 2007, 365:90–108.CrossRefPubMed
48.
go back to reference Ilhan F, Celiker U, Godekmerdan A, Kan E: The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res 2005, 36:372–375.CrossRefPubMed Ilhan F, Celiker U, Godekmerdan A, Kan E: The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res 2005, 36:372–375.CrossRefPubMed
49.
go back to reference • Hurst J, Prinz N, Lorenz M, et al.: TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683–691. This article discusses the first presentation of a new signaling cascade downstream of TLR7 and TLR8 toward IL-1β and Caspase-1. • Hurst J, Prinz N, Lorenz M, et al.: TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683–691. This article discusses the first presentation of a new signaling cascade downstream of TLR7 and TLR8 toward IL-1β and Caspase-1.
Metadata
Title
The Roll of Toll-like Receptors in the Antiphospholipid Syndrome
Authors
Julia Hurst
Mareike Lorenz
Nadine Prinz
Philipp von Landenberg
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 1/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-009-0079-0

Other articles of this Issue 1/2010

Current Rheumatology Reports 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.